Zhongnan Medical Journal Press

Home Results

A total of 6 result was found. Results that relate to Tislelizumab

Cost-utility analysis of tislelizumab versus sorafenib as first-line treatment for advanced unresectable hepatocellular carcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,27(1):109-116.
7301 times 1681 times

SU Zhan CHE Jinhui PEI Ruifeng

Hepatocellular carcinoma Tislelizumab Sorafenib Partition survival model Pharmacoeconomic analysis
Details
First-line treatment with tislelizumab for advanced non-small cell lung cancer: a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2024,33(7):790-800.
10202 times 1767 times

LI Wenyan PAN Xiding JIE Qiong LI Yuanyuan TANG Mufei

Tislelizumab Non-small cell lung cancer First-line treatment Rapid health technology assessment
Details
A case report of psoriasis-like rash caused by tislelizumab

Published on Chinese Journal of Pharmacoepidemiology 2024,33(10):1189-1195.
10883 times 2151 times

LI Jie WANG Ronghua XIE Xiaolei

Tislelizumab Psoriasis-like rash Adverse drug reaction
Details
A case report of immune-related multisystem adverse reactions caused by tislelizumab

Published on Chinese Journal of Pharmacoepidemiology 2025,34(3):359-364.
12019 times 1698 times

SONG Qiuyan TAI Qirui ZHANG Bikui LUO Zhiying SUN Bao LIU Wenhui

Tislelizumab Myasthenia gravis Myositis Myocarditis Liver function damage Immune-related adverse reaction
Details
Efficacy and safety of Tislelizumab combined with chemotherapy in the treatment of non-small cell lung cancer: a Meta-analysis

Published on New Medicine 2025,35(4):442-451.
9287 times 1582 times

WANG Kuan TAN Xiao GUO Yanni

Non-small cell lung cancer Tislelizumab Chemotherapy Effectiveness Safety Meta-analysis
Details
Efficacy and safety of tislelizumab combined with anlotinib in the treatment of advanced non-small cell lung cancer: a Meta-analysis

Published on Chinese Journal of Pharmacoepidemiology 2025,34(7):785-794.
8400 times 1160 times

TENG Xinli LIU Bin XIU Junli ZHOU Xiaohong

Tislelizumab Anlotinib Non-small cell lung cancer Meta-analysis Systematic review
Details